These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 33989664)

  • 21. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
    Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer.
    Ju L; Zhou C
    Cancer Biomark; 2013; 13(5):329-36. PubMed ID: 24440972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z; Gao W
    Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
    Xie M; Zhang L; He CS; Xu F; Liu JL; Hu ZH; Zhao LP; Tian Y
    J Cell Biochem; 2012 May; 113(5):1501-13. PubMed ID: 22173954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SOX9 drives the epithelial-mesenchymal transition in non-small-cell lung cancer through the Wnt/β-catenin pathway.
    Huang JQ; Wei FK; Xu XL; Ye SX; Song JW; Ding PK; Zhu J; Li HF; Luo XP; Gong H; Su L; Yang L; Gong LY
    J Transl Med; 2019 May; 17(1):143. PubMed ID: 31060551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
    Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CIB2 mediates acquired gefitinib resistance by inducing ZEB1 expression and epithelial-mesenchymal transition.
    Zhou FM; Wang KK; Wang LH; Qiu JG; Wang W; Liu WJ; Wang L; Jiang BH
    Aging (Albany NY); 2024 Sep; 16(17):12277-12292. PubMed ID: 39264588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer.
    Rastogi I; Rajanna S; Webb A; Chhabra G; Foster B; Webb B; Puri N
    Biochem Biophys Res Commun; 2016 Sep; 477(4):937-944. PubMed ID: 27396618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
    Jia Z; Zhang Y; Yan A; Wang M; Han Q; Wang K; Wang J; Qiao C; Pan Z; Chen C; Hu D; Ding X
    Cell Death Dis; 2020 Aug; 11(8):670. PubMed ID: 32820157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial-mesenchymal transition through targeting major vault protein (MVP).
    Lou L; Wang J; Lv F; Wang G; Li Y; Xing L; Shen H; Zhang X
    Cell Oncol (Dordr); 2021 Feb; 44(1):109-133. PubMed ID: 32894437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
    Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
    Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer.
    Wang SP; Hsu YP; Chang CJ; Chan YC; Chen CH; Wang RH; Liu KK; Pan PY; Wu YH; Yang CM; Chen C; Yang JM; Liang MC; Wong KK; Chao JI
    Biochem Pharmacol; 2021 Nov; 193():114792. PubMed ID: 34597670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
    Zhang Y; Zhang Q; Chen H; Wang C
    Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer.
    Zhao L; Wang Y; Sun X; Zhang X; Simone N; He J
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic role of annexin A2 and cancer-associated fibroblasts in advanced non-small cell lung cancer: Implication in epithelial-mesenchymal transition and gefitinib resistance.
    Ibrahim FM; Helal DS; Ali DA; Abd-Ellatif RN; Elkady AM; Sharshar R; Gharib F; Abo Elnasr M; El-Guindy DM
    Pathol Res Pract; 2023 Jan; 241():154293. PubMed ID: 36586309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib.
    Ming JX; Wang ZC; Huang Y; Ohishi H; Wu RJ; Shao Y; Wang H; Qin MY; Wu ZL; Li YY; Chang Zhou S; Chen H; Liu H; Xu R
    J Ethnopharmacol; 2021 Jan; 265():113302. PubMed ID: 32860893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
    Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
    Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.